The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding
Open accessAbstract
BMS-378806 is a recently discovered small molecule HIV-1 inhibitor that blocks viral entrance to cells. The compound exhibits potent inhibitory activity against a panel of R5-(virus using the CCR5 coreceptor), X4-(virus using the CXCR4 coreceptor), and R5/X4 HIV-1 laboratory and clinical isolates of the B subtype (median EC 50 of 0.04 μM) in culture assays. BMS-378806 is selective for HIV-1 and inactive against HIV-2, SIV and a panel of other viruses, and exhibits no significant cytotoxicity in the 14 cell types tested (concentration for 50% reduction of cell growth, >225 μM). Mechanism of action studies demonstrated that BMS-378806 binds to gp120 and inhibits the interactions of the HIV-1 envelope protein to cellular CD4 receptors. Further confirmation that BMS-378806 targets the envelope in infected cells was obtained through the isolation of resistant variants and the mapping of resistance substitutions to the HIV-1 envelope. In particular, two substitutions, M426L and M475I, are situated in the CD4 binding pocket of gp120. Recombinant HIV-1 carrying these two substitutions demonstrated significantly reduced susceptibility to compound inhibition. BMS-378806 displays many favorable pharmacological traits, such as low protein binding, minimal human serum effect on anti-HIV-1 potency, good oral bioavailability in animal species, and a clean safety profile in initial animal toxicology studies. Together, the data show that BMS-378806 is a representative of a new class of HIV inhibitors that has the potential to become a valued addition to our current armamentarium of antiretroviral drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., & Hendrickson, W. A. (1998) · Nature · doi:10.1038/31405 · Cited by 2,964
The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens
Wyatt, R., & Sodroski, J. (1998) · Science · doi:10.1126/science.280.5371.1884 · Cited by 1,598
Chan, D. C., & Kim, P. S. (1998) · Cell · doi:10.1016/s0092-8674(00)81430-0 · Cited by 1,277
Antiretroviral-Drug Resistance among Patients Recently Infected with HIV
Little, S. J., Holte, S., Routy, J.-P., Daar, E. S., Markowitz, M., Collier, A. C., Koup, R. A., Mellors, J. W., Connick, E., Conway, B., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013552 · Cited by 1,140
Kilby, J. M., Hopkins, S., Venetta, T. M., DiMassimo, B., Cloud, G. A., Lee, J. Y., Alldredge, L., Hunter, E., Lambert, D., Bolognesi, D., et al. (1998) · Nature Medicine · doi:10.1038/3293 · Cited by 987
Robertson, D. L., Anderson, J. P., Bradac, J. A., Carr, J. K., Foley, B., Funkhouser, R. K., Gao, F., Hahn, B. H., Kalish, M. L., Kuiken, C., et al. (2000) · Science · doi:10.1126/science.288.5463.55d · Cited by 964
Human Retroviruses and Aids - 1999
Kuiken, C., & Foley, B. (1999) · doi:10.2172/1186019 · Cited by 952
Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America
Lalezari, J. P., Henry, K., O'Hearn, M., Montaner, J. S. G., Piliero, P. J., Trottier, B., Walmsley, S., Cohen, C., Kuritzkes, D. R., Eron, J. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035026 · Cited by 914
Starcich, B. R., Hahn, B. H., Shaw, G. M., McNeely, P. D., Modrow, S., Wolf, H., Parks, E. S., Parks, W. P., Josephs, S. F., Gallo, R. C., et al. (1986) · Cell · doi:10.1016/0092-8674(86)90778-6 · Cited by 767
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor
Donzella, G. A., Schols, D., Lin, S. W., Esté, J. A., Nagashima, K. A., Maddon, P. J., Allaway, G. P., Sakmar, T. P., Henson, G., DeClercq, E., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-072 · Cited by 760
Weislow, O. S., Kiser, R., Fine, D. L., Bader, J., Shoemaker, R. H., & Boyd, M. R. (1989) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/81.8.577 · Cited by 685
Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen
Smith, D. H., Byrn, R. A., Marsters, S. A., Gregory, T., Groopman, J. E., & Capon, D. J. (1987) · Science · doi:10.1126/science.3500514 · Cited by 485
Trkola, A., Pomales, A. B., Yuan, H., Korber, B., Maddon, P. J., Allaway, G. P., Katinger, H., Barbas, C. F., Burton, D. R., & Ho, D. D. (1995) · Journal of Virology · doi:10.1128/jvi.69.11.6609-6617.1995 · Cited by 480
A soluble CD4 protein selectively inhibits HIV replication and syncytium formation
Hussey, R. E., Richardson, N. E., Kowalski, M., Brown, N. R., Chang, H.-C., Siliciano, R. F., Dorfman, T., Walker, B., Sodroski, J., & Reinherz, E. L. (1988) · Nature · doi:10.1038/331078a0 · Cited by 427
Structures of HIV-1 gp120 Envelope Glycoproteins from Laboratory-Adapted and Primary Isolates
Kwong, P. D., Wyatt, R., Majeed, S., Robinson, J., Sweet, R. W., Sodroski, J., & Hendrickson, W. A. (2000) · Structure · doi:10.1016/s0969-2126(00)00547-5 · Cited by 390
Nussbaum, O., Broder, C. C., & Berger, E. A. (1994) · Journal of Virology · doi:10.1128/jvi.68.9.5411-5422.1994 · Cited by 338
Hill, C. M., Deng, H., Unutmaz, D., Kewalramani, V. N., Bastiani, L., Gorny, M. K., Zolla-Pazner, S., & Littman, D. R. (1997) · Journal of Virology · doi:10.1128/jvi.71.9.6296-6304.1997 · Cited by 199
Kilby, J. M., Lalezari, J. P., Eron, J. J., Carlson, M., Cohen, C., Arduino, R. C., Goodgame, J. C., Gallant, J. E., Volberding, P., Murphy, R. L., et al. (2002) · AIDS Research and Human Retroviruses · doi:10.1089/088922202760072294 · Cited by 198
Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes
Martin, L., Stricher, F., Missé, D., Sironi, F., Pugnière, M., Barthe, P., Prado-Gotor, R., Freulon, I., Magne, X., Roumestand, C., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt768 · Cited by 188
AIDS and Other Manifestations of HIV Infection
(2004) · Elsevier eBooks · doi:10.1016/b978-0-12-764051-8.x5000-8 · Cited by 131
Rose, R. E., Gong, Y., Greytok, J. A., Bechtold, C. M., Terry, B., Robinson, B. S., Alam, M., Colonno, R. J., & Lin, P. F. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.4.1648 · Cited by 116
Self-citationWegner, S. A., Brodine, S. K., Mascola, J. R., Tasker, S. A., Shaffer, R. A., Starkey, M. J., Barile, A. J., Martin, G. J., Aronson, N., Emmons, W. W., et al. (2000) · AIDS · doi:10.1097/00002030-200005260-00013 · Cited by 115
LaBranche, C. C., GALASSO, G., Moore, J. P., Bolognesi, D. P., Hirsch, M., & Hammer, S. (2001) · Antiviral Research · doi:10.1016/s0166-3542(01)00130-9 · Cited by 105
Baseline Susceptibility of Primary Human Immunodeficiency Virus Type 1 to Entry Inhibitors
Labrosse, B., Labernardière, J., Dam, E., Trouplin, V., Skrabal, K., Clavel, F., & Mammano, F. (2002) · Journal of Virology · doi:10.1128/jvi.77.2.1610-1613.2003 · Cited by 92
Recombinant CD4‐IgG2 in Human Immunodeficiency Virus Type 1–Infected Children: Phase 1/2 Study
Shearer, W. T., Israel, R. J., Starr, S. E., Fletcher, C. V., Wara, D. W., Rathore, M. H., Church, J. A., Deville, J. G., Fenton, T., Graham, B., et al. (2000) · The Journal of Infectious Diseases · doi:10.1086/317622 · Cited by 78
McCombie, S. W., Tagat, J. R., Vice, S. F., Lin, S., Steensma, R. W., Palani, A., Neustadt, B. R., Baroudy, B. M., Strizki, J., Endres, M. J., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00918-6 · Cited by 52
HIV-1 entry inhibitors: new targets, novel therapies
Pierson, T. C., & Doms, R. W. (2003) · Immunology Letters · doi:10.1016/s0165-2478(02)00235-3 · Cited by 34
Current strategies in the treatment of HIV infection
Cohen, O. J., & Fauci, A. S. (2002) · Disease-a-Month · doi:10.1067/mda.2002.124659 · Cited by 30
Cited by
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476
Harrison, S. C. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1456 · Cited by 1,190
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,152
Mode of antiviral action of silver nanoparticles against HIV-1
Lara, H. H., Ayala-Nuñez, N. V., Ixtepan-Turrent, L., & Rodriguez-Padilla, C. (2010) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-8-1 · Cited by 1,061
A review on recent developments of indole-containing antiviral agents
Zhang, M.-Z., Chen, Q., & Yang, G.-F. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.065 · Cited by 887
Metadata
- Authors
- Lin, P.-F., Blair, W., Wang, T., Spicer, T., Guo, Q., Zhou, N., Gong, Y.-F., Wang, H.-G. H., Rose, R., Yamanaka, G., Robinson, B., Li, C.-B., Fridell, R., Deminie, C., Demers, G., Yang, Z., Zadjura, L., Meanwell, N., & Colonno, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2003-08-20
- Volume
- 100
- Issue
- 19
- Pages
- 11013-11018
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2110838631
- Cited by
- 357
- References
- 28
- FWCI
- 15.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.